Colorectal cancer: current care, future innovations and economic considerations

References

• Cancer Research UK. British cancer death rates. Br. Med. J. 328, 303 (2004).
   Google Scholar
• Maxwell-Armstrong CA, Scholefield JH. Colorectal cancer. In: Clinical Evidence (Volume 10). Godlee F (Ed.). BMJ Publishing group, London, UK 509–517 (2003).
   Google Scholar
• Bingham SA, Day NE, Luben R et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361(9368), 1496–1501 (2003).
   PubMed Web of Science ®Google Scholar
• Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma–carcinoma sequence. Br. J. Surg. 89, 845–860 (2002).
   PubMed Web of Science ®Google Scholar
• Smith JJ, Lee J, Burke C, Contractor KB, Dawson PM. Major colorectal cancer resection should not be denied to the elderly. Eur. J. Surg. Oncol. 28, 661–666 (2002).
   PubMedGoogle Scholar
• Cancer Line UK. Colorectal cancer. In: Cancer line UK (2003).
   Google Scholar
• Minsky BD. Multidisciplinary case teams: an approach to the future management of advanced colorectal cancer. Br. J. Cancer 77(Suppl. 2), 1–4 (1998).
   PubMed Web of Science ®Google Scholar
• Macafee DAL. The cost of screening and caring for patients with colorectal cancer. Nottingham (2005).
   Google Scholar
• Northover J. Follow-up after curative surgery for colorectal cancer. The Association of Coloproctology of Great Britain and Ireland. London, UK (2003).
   Google Scholar
• Lund JN, Scholefield JH, Grainge MJ et al. Risks, costs and compliance limit colorectal adenoma surveillance: lessons from a randomised trial. Gut49, 91–96 (2001).
   PubMed Web of Science ®Google Scholar
• Memon MA, Beckingham IJ. Surgical resection of colorectal liver metastases. Colorectal Dis. 3(6), 361–372 (2001).
   PubMedGoogle Scholar
• Beard SM, Holmes M, Price C, Majeed AW. Hepatic resection for colorectal liver metastases: a cost-effectiveness analysis. Ann. Surg.232(6), 763–776 (2000).
   PubMed Web of Science ®Google Scholar
• Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J. Clin. Oncol.23(33), 8490–8499 (2005).
   PubMed Web of Science ®Google Scholar
• Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer. Br. Med. J. 321, 531–535 (2000).
   Google Scholar
• Nolte W, Ramadori G. Recent aspects of palliative treatment of metastasised colorectal carcinoma. Med. Clin. (Munich) 96(9), 521–528 (2001).
   PubMedGoogle Scholar
• Coyle D, Small N, Ashworth A et al. Costs of palliative care in the community, in hospitals and in hospices in the UK. Crit. Rev. Oncol. Hematol. 32, 71–85 (1999).
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Cancer Report. New York, USA (2003).
   Google Scholar
• Regueiro CR, AGA Future Trends Committee. AGA Future Trends Committee Report: colorectal cancer: a qualitative review of emerging screening and diagnostic technologies. Gastroenterology129, 1083–1103 (2005).
   PubMed Web of Science ®Google Scholar
• Whynes DK, Neilson AR, Robinson MHE, Hardcastle JD. Colorectal cancer screening and quality of life. Qual. Life Res. 3(3), 191–198 (1994).
   PubMed Web of Science ®Google Scholar
• Doorbar J, Cubie H. Molecular basis for advances in cervical screening. Mol. Diagn. 9(3), 129–142 (2005).
   PubMedGoogle Scholar
• Muir KR, Logan RFA. Aspirin, NSAIDs and colorectal cancer–what do the epidemiological studies show and what do they tell us about the modus operandi? Apoptosis4(5), 389–396 (1999).
   PubMed Web of Science ®Google Scholar
• Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 10(348), 883–890 (2003).
   Google Scholar
• Subramanian S, Klosterman M, Amonkar MM, Hunt TL. Adherence with colorectal cancer screening guidelines: a review. Preventive Medicine 38, 536–550 (2004).
   Google Scholar
• Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer 2004. CA Cancer J. Clin.54, 41–52 (2004).
   PubMed Web of Science ®Google Scholar
• Garvican L. Planning for a possible national colorectal cancer screening programme. J. Med. Screen. 5(4), 187–194 (1998).
   PubMed Web of Science ®Google Scholar
• Robert G, Brown J, Garvican L. Cost of quality management and information provision for screening: colorectal cancer screening. J. Med. Screen. 7(1), 31–34 (2000).
   PubMed Web of Science ®Google Scholar
• Towler BP, Irwig L, Glasziou P. Screening for colorectal cancer using the faecal occult blood test, haemoccult. Cochrane Database Syst. Rev. 2 (2000).
   Google Scholar
• UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 359, 1291–1300 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor SA, Halligan S, Saunders BP et al. Use of multidetector-row CT colonography for detection of colorectal neoplasia in patients referred via the Department of Health ‘2-week-wait’ initiative. Clin. Radiol. 58, 855–861 (2003).
   PubMed Web of Science ®Google Scholar
• Bowles CJA, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow. Gut53, 277–283 (2004).
   PubMed Web of Science ®Google Scholar
• Young GP, St John DJ, Winawer SJ, Rozen P, WHO (World Health Organization), OMED(World Organization for Digestive Endoscopy). Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO and OMED report. Am. J. Gastroenterol. 97(10), 2499–2507 (2002).
   PubMed Web of Science ®Google Scholar
• Whynes DK, Walker AR, Chamberlain JO, Hardcastle JD. Screening and the costs of treating colorectal cancer. Br. J. Cancer 68, 965–968 (1993).
   PubMed Web of Science ®Google Scholar
• Hardcastle JD, Balfour TW, Amar SS. Screening for symptomless colorectal cancer by testing for occult blood in General Practice. Lancet 1, 791–793 (1980).
   Google Scholar
• Walker AR, Whynes DK. Participation and screening programmes for colorectal cancer: more would be better? J. Health Econ. 10, 207–225 (1991).
   PubMed Web of Science ®Google Scholar
• Schroy PC, Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am. J. Prevent. Med.28(2), 208–214 (2005).
   PubMed Web of Science ®Google Scholar
• Ling BS, Moskowitz MA, Wachs D, Pearson B, Schroy PC. Attitudes toward colorectal cancer screening tests. J. Gen. Int. Med. 16(12), 822–830 (2001).
   PubMed Web of Science ®Google Scholar
• Robinson MHE, Hardcastle JD. Screening for Colorectal Cancer – Who, When and How. Oxford, Blackwell Science, UK (2000).
   Google Scholar
• Feldman AL, Espina V, Petricoin EF, Liotta LA, Rosenblatt KP. Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery135(3), 243–247 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson JF. The promise of disease proteomics: faster detection, diagnosis, and drug development. Ann. Intern. Med. 140(4), 317–319 (2004).
   PubMed Web of Science ®Google Scholar
• Brunagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. J. Cell. Biochem. 91(2), 365–374 (2004).
   PubMed Web of Science ®Google Scholar
• Sirieix PS, O’Donovan M, Brown J, Save V, Coleman N, Fitzgerald RC. Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett’s esophagus. Clin. Cancer Res.9(7), 2560–2566 (2003).
   PubMed Web of Science ®Google Scholar
• Davies RJ, Freeman A, Morris LS et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 359(9321), 1917–1919 (2002).
   PubMed Web of Science ®Google Scholar
• Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology127(2), 422–427 (2004).
   PubMed Web of Science ®Google Scholar
• Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am. J. Gastroenterol. 100(6), 1393–1403 (2005).
   PubMed Web of Science ®Google Scholar
• Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. Br. Med. J. 331(7524), 1047 (2005).
   PubMedGoogle Scholar
• Pfau PR, Sivak MVJ. Endoscopic diagnostics. Gastroenterology 120(3), 763–781 (2001).
   Google Scholar
• Taylor SA, Halligan S, O’Donnell C et al. Cardiovascular effects at multi-detector row CT colonography compared with those at conventional endoscopy of the colon. Radiology229, 782–790 (2003).
   PubMed Web of Science ®Google Scholar
• White TJ, Avery GR, Kennan N, Syed A, Hartley JE, Monson JRT. Virtual versus conventional colonoscopy–patient preference and tolerability. Colorectal Dis. 6S1, 74 (2004).
   Google Scholar
• Miao YM, Amin Z, Healy J et al. A prospective single centre study comparing computed tomography pneumocolon against colonoscopy in the detection of colorectal neoplasms. Gut47(6), 832–837 (2000).
   PubMed Web of Science ®Google Scholar
• Kahi CJ, Rex DK. Current and future trends in colorectal cancer screening. Cancer Metastasis Rev. 23, 137–144 (2004).
   PubMed Web of Science ®Google Scholar
• Rabaneck L. Is computed tomographic colonography effective for colorectal cancer screening. Can. Med. Ass. J.170(9), 1392 (2004).
   Web of Science ®Google Scholar
• Cotton PB, Durkalski VL, Pineau BC et al. Computed tomographic colonography (virtual colonoscopy). A multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 291(14), 1713–1719 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson CD, Harmsen WS, Wilson LA et al. Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. Gastroenterology125(2), 311–319 (2003).
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology129(4), 1151–1162 (2005).
   PubMed Web of Science ®Google Scholar
• Kim J, Czernin J, Allen-Auerbach M et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J. Nucl. Med. 46(4), 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Artiko V, Obradovic V, Davidovic B et al. Radioimmunodetection of colorectal carcinoma. Hepatogastroenterology50(52), 1029–1031 (2003).
   PubMedGoogle Scholar
• Thaler K, Kanneganti S, Khajanchee Y, Wilson C, Swanstrom L, Hansen P. The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis. Arch. Surg. 140(8), 727–734 (2005).
   PubMedGoogle Scholar
• Taplin SH, Barlow W, Urban N et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J. Natl Cancer Inst. 87(6), 417–426 (1995).
   PubMed Web of Science ®Google Scholar
• Whynes DK, Walker AR, Hardcastle JD. Cost-effective screening stratergies for colorectal cancer. J. Pub. Health Med. 14(1), 43–49 (1992).
   PubMedGoogle Scholar
• Kehlet H, Wilmore DW. Multimodal stratergies to improve surgical outcome. Am. J. Surg. 183, 630–641 (2002).
   PubMed Web of Science ®Google Scholar
• Guillou P, Quirke P, Thorpe H et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 365(9472), 1718–1726 (2005).
   PubMed Web of Science ®Google Scholar
• Macafee DAL, Maxwell-Armstrong CA, Scholefield JH. Laparoscopic colorectal cancer surgery. Expert Rev. Anticancer Ther.3(4), 484–492 (2003).
   PubMedGoogle Scholar
• Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284(8), 1008–1015 (2000).
   PubMed Web of Science ®Google Scholar
• Lidder PG, Hosie KB. Rectal cancer: the role of radiotherapy. Dig. Surg. 22(22), 41–48 (2005).
   PubMed Web of Science ®Google Scholar
• Van den Brink M, Van den Hout WB, Stigglebout AM et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the dutch colorectal cancer group. J. Clin. Oncol. 22(2), 244–253 (2004).
   PubMed Web of Science ®Google Scholar
• Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Int. Med. J. 33(3), 119–124 (2003).
   Google Scholar
• Twelves C, Boyer M, Findlay M et al. Capecitabine (Xeloda®) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur. J. Cancer 37(5), 597–604 (2001).
   PubMed Web of Science ®Google Scholar
• Marsh S. Pharmacogenetics of colorectal cancer. Expert Opin. Pharmacother. 6(15), 2607–2616 (2005).
   PubMed Web of Science ®Google Scholar
• Hale JP, Cohen DR, Maughan TS, Stephens RJ. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br. J. Cancer 86, 1684–1690 (2002).
   PubMed Web of Science ®Google Scholar
• Norum J, Balteskard L, Edna TH, Laino R, Wahlby L, Ronning G. Ralitrexed or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focussing on quality of life, patient's preference and health economics. J. Chemother. 14(3), 301–308 (2002).
   PubMed Web of Science ®Google Scholar
• Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Tech. Assess. 7(32), 1–122 (2003).
   PubMedGoogle Scholar
• Schilsky RL. First-line treatment options for patients with metastatic colorectal cancer. Nat. Clin. Pract. Oncol. 1(2), 70–71 (2004).
   PubMedGoogle Scholar
• Bottomley A. Metastatic colorectal cancer: treatment challenges and quality of life. Lancet 359, 1537–1538 (2002).
   PubMed Web of Science ®Google Scholar
• Flechtner H, Bottomley A. Fatigue assessment in cancer clinical trials. Expert Rev. Pharmacoeconomics Outcomes Res. 2, 89–92 (2002).
   Google Scholar
• Glimelius B, Hoffman K, Graf W. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann. Oncol. 6, 267–274 (1995).
   PubMed Web of Science ®Google Scholar
• Evans L. Estimated basic costings of loop ileostomist stoma equipment needs. Paper. Derby, Derby City Hospital (2004).
   Google Scholar
• British Society of Gastroenterology, Association of Coloproctology for Great Britain and Ireland, Scholefield JH, Steele RJC. Guidelines for follow up after resection of colorectal cancer. Gut51, v3–v5 (2002).
   PubMedGoogle Scholar
• Renehan AG, O’Dwyer PJ, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. Br. Med. J. 328, 81–84 (2004).
   PubMedGoogle Scholar
• Korner H, Soreide K, Stokkeland PJ, Soreide JA. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J. Gastrointest. Surg. 9(3), 320–328 (2005).
   PubMed Web of Science ®Google Scholar
• Secco GB, Fardelli R, Gianquinto D et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur. J. Surg. Oncol. 28(4), 418–423 (2002).
   PubMed Web of Science ®Google Scholar
• Oeppen J, Vaupel JW. Broken limits to life expectancy. Science296, 1029–1031 (2002).
   PubMed Web of Science ®Google Scholar
• Ward S, Cowan J. Analysis of the potential cost impact of the guidance on cancer services: ‘Improving outcomes in colorectal cancer’ Expansion in endoscopy capacity – draft for 2nd consultation. Sheffield, School of Health and Related Research, University of Sheffield, UK (2003).
   Google Scholar
• Sikora K, Bosanquet N. Cancer care in the United Kingdom: new solutions are needed. Br. Med. J. 327, 1044–1046 (2003).
   PubMedGoogle Scholar
• Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg.224(4), 520–552 (1996).
   Google Scholar
• Rozen P. Implementing colorectal cancer screening: group 2 report. Endoscopy36, 354–358 (2004).
   PubMed Web of Science ®Google Scholar